Clinical trial
Phase 2, Double-Blind Randomized, 3-way Cross-Over Liquid Meal Study With Optimal Doses of SC Administered Insulin Lispro With and Without rHuPH20 and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Patients With T2DM
NCT00916357 is registered in ClinicalTrials.gov with Halozyme Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2, Double-Blind Randomized, 3-way Cross-Over Liquid Meal Study With Optimal Doses of SC Administered Insulin Lispro With and Without rHuPH20 and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Patients With T2DM
- Lead sponsor
- Halozyme Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2009
- Completion date
- November 30, 2009
- Enrollment
- 23 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.